Recently, it has been demonstrated that IDH2 inhibition enhances proteasome inhibitors (PIs) responsiveness in multiple myeloma (MM), mantle cell lymphoma, and Burkitt lymphoma cell lines, as well as in primary CD138+ cells from MM patients [101]. The gene discussed is IDH2; the disease is Miyoshi myopathy.